Please login to the form below

Endocyte

This page shows the latest Endocyte news and features for those working in and with pharma, biotech and healthcare.

Merck's vintafolide fails ovarian cancer trial

Merck's vintafolide fails ovarian cancer trial. Major blow for drug’ s original developers Endocyte. ... Shares in Endocyte are currently hovering above $6.50, having traded as high as $33.70 in the last 12 months.

Latest news

EMA backs Janssen rare disease drug for approval

it. Staying in the orphan disease area the CHMP also gave the nod to Endocyte's Vynfinit (vintafolide), a treatment for platinum-resistant ovarian cancer, along with two companion diagnostic drugs
Boehringer/Lilly's empagliflozin among CHMP recommendations

There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).
Late-stage ovarian cancer

Endocyte's vintafolide is a folate-targeted conjugate composed of a folate molecule plus a vinca alkaloid, which acts as a microtubule destabilising agent. ... Phase III studies of vintafolide for the treatment of platinum-resistant ovarian cancer are
Merck's vintafolide shows its worth in ovarian cancer

unlikely to be superior to docetaxel alone, caused a massive reduction in the shares of Endocyte, the US firm which originally developed it. ... Along with Merck, Endocyte has been "building up our commercial capabilities to prepare for a potential
AZ licenses Merck ovarian cancer drug

vintafolide for ovarian cancer, which Merck licensed from Endocyte last year in a deal valued at up to $1bn.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Charting a course for expansion

and eastern Europe - and US biotech Endocyte.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Endocyte appoints Parexel's Scot Harper to oversee clinical trials

Endocyte appoints Parexel's Scot Harper to oversee clinical trials. He also previously served at Novartis and Lilly. ... In addition, Endocyte says it has three new drug candidates scheduled to enter the clinic before the end of 2014.
Endocyte brings in senior figures from BMS and Amgen

Endocyte brings in senior figures from BMS and Amgen. Appoints Torsten Hoof and Ulf Staginnus as company prepares to launch cancer drugs. ... The two additions follow the hire in July 2012 of Endocyte's first chief commercial officer, David Meek from

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Home based, Senior Medical Writer, Medical Communications: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Business Unit Head, Medical Communications, London: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Account Manager: £40, 000 - £45, 000 benefits

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Client Services Director – Healthcare Advertising - London: Neg

Home based, Editorial Team Leader, Medical Communications: Excellent package

Senior Account Manager: Competitive salary commensurate with experience

Home based, Principal Medical Writer, Medical Communications: Excellent package

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Client Services Director - Med Comms: Great salary and bebefits

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Home based, Chief Medical Writer, Medical Communications: Excellent package

Senior Project Manager - Medical Writing: Great salary and bebefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Editorial Director – Medical Education (MedComms): Neg

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Subscribe to our email news alerts

PMHub

Add my company

OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....